Ziftomenib Patent Expiration
Ziftomenib was first introduced by Kura Oncology Inc
Ziftomenib Patents
Given below is the list of patents protecting Ziftomenib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Komzifti | US12410184 | Crystalline Forms Of A Menin Inhibitor | Jul 16, 2044 | Kura |
| Komzifti | US12521396 | Pharmaceutical Compositions Comprising A Menin Inhibitor | Jul 16, 2044 | Kura |
| Komzifti | US11944627 | Methods For Treating Hematological Malignancies And Ewing'S Sarcoma | Sep 06, 2038 | Kura |
| Komzifti | US10781218 | Substituted Inhibitors Of Menin-Mll And Methods Of Use | Mar 15, 2037 | Kura |
| Komzifti | US11673898 | Substituted Inhibitors Of Menin-Mll And Methods Of Use | Mar 15, 2037 | Kura |
| Komzifti | US10869868 | Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression In Npm1 Mutant Leukemia | Jan 26, 2037 | Kura |
| Komzifti | US10077271 | Methods And Compositions For Inhibiting The Interaction Of Menin With Mll Proteins | Mar 16, 2036 | Kura |
| Komzifti | US10174041 | Methods And Compositions For Inhibiting The Interaction Of Menin With Mll Proteins | Mar 16, 2036 | Kura |
Ziftomenib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ziftomenib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia | M.D. Anderson Cancer Center | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | Kyowa Kirin Co., Ltd. | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| Ziftomenib Maintenance Post Allo-HCT | Massachusetts General Hospital | NA |
RECRUITING
(Mar 1, 2026)
| PHASE1 |